Antitumor effects of 3-[p-(N,N-bis-(2'-chloroethyl)amino)-phenyl]-L- alanine conjugated with human immunoglobulin (K18).
K18 (3-[p-(N,N-bis(2'-chloroethyl)amino)- phenyl]-L-alanine conjugated with human immunoglobulin) is a newly developed antitumor agent. LD50 values of K18 in animals were quite high, suggesting its low acute toxicity. This drug showed anti-tumorigenicity not only on an experimental animal tumor (Walker 256), but also on a human tumor transplantable into nude mice (RCC-13). A distribution study clarified the unique properties of K18 to accumulate and remain in the tumor site with a high rate.
Yoshimura
M
M
Kureha Chemical Ind. Co., Ltd., Tokyo, Japan.
Niimura
K
K
Fujii
M
M
Matsunaga
K
K
Oguchi
Y
Y
Fujii
T
T
Muto
S
S
Furusho
T
T
Yoshikumi
C
C
D000818:Animals; D002279:Carcinoma 256, Walker / Q000188:drug therapy*; D004285:Dogs; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D051379:Mice; D008807:Mice, Inbred BALB C; D008813:Mice, Inbred ICR; D008819:Mice, Nude; D051381:Rats; D011919:Rats, Inbred Strains; D014183:Transplantation, Heterologous
D007136:Immunoglobulins; D008558:Melphalan